Pathology in United States: Human Papillomavirus Infections – Pipeline Review, H1 2012

• Publication date: March 2013
• Report size: 134 pages

This report provides data on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 'Human Papillomavirus Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary database...

This report provides data on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 'Human Papillomavirus Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Human Papillomavirus Infections.
- A review of the Human Papillomavirus Infections products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Human Papillomavirus Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Human Papillomavirus Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Drug And Medication Industry

Table of Contents

Data table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global March kets Direct Report Coverage 9
Human Papillomavirus Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Human Papillomavirus Infections 11
Human Papillomavirus Infections Therapeutics under Development by Firms 13
Human Papillomavirus Infections Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Human Papillomavirus Infections Therapeutics – Products under Development by Firms 22
Human Papillomavirus Infections Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Human Papillomavirus Infections Therapeutics Development 24
Helix BioPharma Corp. 24
Merck & Co., Inc. 25
MediGene AG 26
Alfacell Corporation 27
Crucell N.V. 28
Bio-Bridge Science, Inc. 29
Amarillo Biosciences, Inc. 30
Starpharma Holdings Limited 31
Transgene SA 32
Nutri Pharma ASA 33
BioMAS Ltd. 34
Telormedix SA 35
ApoImmune, Inc. 36
PDS Biotechnology Corporation 37
EpiVax, Inc. 38
Lumavita AG 39
BT PHARMA 40
iBio, Inc. 41
Cutanea Life Sciences 42
Genetic Immunity, LLC 43
IRX Therapeutics, Inc. 44
Moberg Derma AB 45
Inviragen, Inc. 46
Human Papillomavirus Infections – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 54
PDS0101 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Interferon Alpha-2b - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HPV Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Interferon Alpha - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TMX-202 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ApoVax104-HPV - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LMV-601 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
IRX-3 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ProCervix - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
V503 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AS101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Isotretinoin + Interferon Alfa-2a - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Candin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Human Papillomavirus Quadrivalent Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
VivaGel - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cidofovir - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TG4001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Mozobil - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Quadrivalent Human Papillomavirus Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Propranolol - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SGN-00101 Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Albuterpenoid - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Albuterpenoid - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
HPV Vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
HupaDerm Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Human Papillomavirus Vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Interferon-Alpha + Ribavirin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
HPV Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
RBT 201 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Limtop - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
HPV Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Silgard - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
HPV Vaccine - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
rAmphinase 2 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Adeno-Associated Virus-Like Particles - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Human Papillomavirus Infections Therapeutics – Drug Profile Updates 100
Human Papillomavirus Infections Therapeutics – Discontinued Products 105
Human Papillomavirus Infections Therapeutics - Dormant Products 106
Human Papillomavirus Infections – Product Development Milestones 108
Featured News & Press Releases 108
January 26, 2012: Hemispherx Biopharma Gains Regulatory Approval In Latin America For Alferon N Injection 108
January 25, 2012: Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis Or Type 1 Diabetes After Vaccination 108
January 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL 109
January 03, 2012: Photocure Completes Enrollment In Phase IIb Study Of Cevira 110
December 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 110
November 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 111
October 26, 2011: New England Journal Of Medicine Publishes Additional Efficacy And Safety Data For Merck's GARDASIL In Males 112
October 25, 2011: CDC Advisory Committee On Immunization Practices Votes For Expanded Use Of GARDASIL In Boys And Young Men 112
October 12, 2011: Helix BioPharma Files IND Clinical Hold Response With FDA For Its Planned Topical Interferon Alpha-2b Phase II/III Efficacy Trial 113
September 16, 2011: Helix BioPharma To Present Data On Interferon Alpha-2b At 27th International Papillomavirus Conference And Clinical Workshop 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116

List of Tables

List of Tables
Number of Products Under Development for Human Papillomavirus Infections, H1 2012 11
Products under Development for Human Papillomavirus Infections – Comparative Analysis, H1 2012 12
Number of Products under Development by Firms, H1 2012 14
Number of Products under Development by Firms, H1 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2012 17
Comparative Analysis by Late Stage Development, H1 2012 18
Comparative Analysis by Mid Clinical Stage Development, H1 2012 19
Comparative Analysis by Early Clinical Stage Development, H1 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 21
Products under Development by Firms, H1 2012 22
Products under Investigation by Universities/Institutes, H1 2012 23
Helix BioPharma Corp., H1 2012 24
Merck & Co., Inc., H1 2012 25
MediGene AG, H1 2012 26
Alfacell Corporation, H1 2012 27
Crucell N.V., H1 2012 28
Bio-Bridge Science, Inc., H1 2012 29
Amarillo Biosciences, Inc., H1 2012 30
Starpharma Holdings Limited, H1 2012 31
Transgene SA, H1 2012 32
Nutri Pharma ASA, H1 2012 33
BioMAS Ltd., H1 2012 34
Telormedix SA, H1 2012 35
ApoImmune, Inc., H1 2012 36
PDS Biotechnology Corporation, H1 2012 37
EpiVax, Inc., H1 2012 38
Lumavita AG, H1 2012 39
BT PHARMA, H1 2012 40
iBio, Inc., H1 2012 41
Cutanea Life Sciences, H1 2012 42
Genetic Immunity, LLC, H1 2012 43
IRX Therapeutics, Inc., H1 2012 44
Moberg Derma AB, H1 2012 45
Inviragen, Inc., H1 2012 46
Assessment by Monotherapy Products, H1 2012 47
Assessment by Combination Products, H1 2012 48
Assessment by Stage and Route of Administration, H1 2012 50
Assessment by Stage and Molecule Type, H1 2012 53
Human Papillomavirus Infections Therapeutics – Drug Profile Updates 100
Human Papillomavirus Infections Therapeutics – Discontinued Products 105
Human Papillomavirus Infections Therapeutics – Dormant Products 106
Human Papillomavirus Infections Therapeutics – Dormant Products (Contd..1) 107

List of Figures

List of Figures
Number of Products under Development for Human Papillomavirus Infections, H1 2012 11
Products under Development for Human Papillomavirus Infections – Comparative Analysis, H1 2012 12
Products under Development by Firms, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 16
Late Stage Products, H1 2012 18
Mid Clinical Stage Products, H1 2012 19
Early Clinical Stage Products, H1 2012 20
Discovery and Pre-Clinical Stage Products, H1 2012 21
Assessment by Monotherapy Products, H1 2012 47
Assessment by Combination Products, H1 2012 48
Assessment by Route of Administration, H1 2012 49
Assessment by Stage and Route of Administration, H1 2012 50
Assessment by Molecule Type, H1 2012 51
Assessment by Stage and Molecule Type, H1 2012 52